Cargando…

Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies

The endogenous opioid system is thought to play an important role in the regulation of mood. Buprenorphine/samidorphan (BUP/SAM) combination is an investigational opioid system modulator for adjunctive treatment of major depressive disorder (MDD). To confirm results from early studies, we report the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fava, Maurizio, Thase, Michael E., Trivedi, Madhukar H., Ehrich, Elliot, Martin, William F., Memisoglu, Asli, Nangia, Narinder, Stanford, Arielle D., Yu, Miao, Pathak, Sanjeev
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303008/ https://www.ncbi.nlm.nih.gov/pubmed/30374191 http://dx.doi.org/10.1038/s41380-018-0284-1

Ejemplares similares

Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder
por: Thase, Michael E., et al.
Publicado: (2019)

Buprenorphine/samidorphan combination for the adjunctive treatment of major depressive disorder: results of a phase III clinical trial (FORWARD-3)
por: Zajecka, John M, et al.
Publicado: (2019)

Evaluation of Opioid Modulation in Major Depressive Disorder
por: Ehrich, Elliot, et al.
Publicado: (2015)

Use of Remifentanil in a Novel Clinical Paradigm to Characterize Onset and Duration of Opioid Blockade by Samidorphan, a Potent μ-Receptor Antagonist
por: Shram, Megan J., et al.
Publicado: (2015)

A Review of Samidorphan: A Novel Opioid Antagonist
por: Chaudhary, Amna Mohyud Din, et al.
Publicado: (2019)

Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study
por: Papakostas, George I., et al.
Publicado: (2020)

Creation of an algorithm for clinical decision support for treatment of opioid use disorder with buprenorphine in primary care
por: dela Cruz, Adriane M., et al.
Publicado: (2021)

Managing opioid withdrawal precipitated by buprenorphine with buprenorphine
por: Oakley, Bridget, et al.
Publicado: (2021)

In vivo Characterization of the Opioid Receptor–Binding Profiles of Samidorphan and Naltrexone in Rats: Comparisons at Clinically Relevant Concentrations
por: Tan, Laura A, et al.
Publicado: (2022)

Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended‐Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens
por: Comer, Sandra D., et al.
Publicado: (2020)

The Facts and Fiction of Olanzapine-Samidorphan Fixed Dose Combination
por: Das, Nileswar, et al.
Publicado: (2022)

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men
por: Ziaaddini, Hassan, et al.
Publicado: (2018)

Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study
por: Correll, Christoph U, et al.
Publicado: (2022)

Advances in the delivery of buprenorphine for opioid dependence
por: Rosenthal, Richard N, et al.
Publicado: (2017)

Role of Buprenorphine in an Adolescent with Opioid Abuse
por: Weesner, Elizabeth, et al.
Publicado: (2022)

Buprenorphine‐naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder
por: Kanervo, Minna M., et al.
Publicado: (2022)

Treatment of opioid dependence with buprenorphine: current update
por: Soyka, Michael
Publicado: (2017)

The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder
por: De Aquino, Joao P., et al.
Publicado: (2021)

Characterization of the Pharmacokinetics of Samidorphan in Healthy Volunteers: Absolute Bioavailability and the Effect of Food and Age
por: Kumar, Vipul, et al.
Publicado: (2019)

Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate
por: Sun, Lei, et al.
Publicado: (2019)

Management of Opioid Addiction With Opioid Substitution Treatments: Beyond Methadone and Buprenorphine
por: Noble, Florence, et al.
Publicado: (2019)

Patients Maintained on Buprenorphine for Opioid Use Disorder Should Continue Buprenorphine Through the Perioperative Period
por: Lembke, Anna, et al.
Publicado: (2019)

Evaluating buprenorphine prescribing and opioid-related health outcomes following the expansion the buprenorphine waiver program
por: Rowe, Christopher L., et al.
Publicado: (2022)

Physiologically‐Based Pharmacokinetic Modeling for Predicting Drug Interactions of a Combination of Olanzapine and Samidorphan
por: Sun, Lei, et al.
Publicado: (2020)

Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia
por: Sun, Lei, et al.
Publicado: (2021)

Combining samidorphan with olanzapine to mitigate weight gain as a side effect in schizophrenia treatment
por: Grywińska, Weronika B., et al.
Publicado: (2023)

The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review
por: Serafini, Gianluca, et al.
Publicado: (2018)

Pattern of buprenorphine abuse among opioid abusers in Nepal
por: Aich, Tapas Kumar, et al.
Publicado: (2010)

Comparison of the Efficacy of Buprenorphine and Clonidine in Detoxification of Opioid-Dependents
por: Ziaaddini, Hassan, et al.
Publicado: (2012)

Sleep problems in opioid dependent patients maintained on buprenorphine
por: Tripathi, R., et al.
Publicado: (2021)

Personalized Care in Opioid Use Disorder maintained on Buprenorphine
por: Elarabi, H., et al.
Publicado: (2022)

Inpatient Buprenorphine Induction for Opioid Use Disorder in Pregnancy
por: Tavakoli, Amin, et al.
Publicado: (2023)

A urinalysis-based study of buprenorphine and non-prescription opioid use among patients on buprenorphine maintenance
por: Balhara, Yatan Pal Singh, et al.
Publicado: (2012)

Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees
por: Wen, Hefei, et al.
Publicado: (2018)

Buprenorphine Dosage and Urine Quantitative Buprenorphine, Norbuprenorphine, and Creatinine Levels in an Office-Based Opioid Treatment Program
por: Furo, Hiroko, et al.
Publicado: (2021)

Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder
por: Connor, Kathryn M, et al.
Publicado: (2017)

A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes
por: Lund, Ingunn O., et al.
Publicado: (2013)

Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet
por: Sun, Lei, et al.
Publicado: (2019)

Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates
por: Cunningham, Jacobi I, et al.
Publicado: (2019)

Opioid Substitution Treatment Using Buprenorphine for Management of Dependence on Natural Opioids: Case Series
por: Kathiresan, Preethy, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_q9ctm5qe97ctq8tp8b5t7c6uh4